News

Investigators believe that the BPDAI may under-estimate overall disease severity in darker skin types.

Investigators observed no reduction in readmission or mortality in a remote monitoring program with incentives for patients previously hospitalized for HF.

The Massachusetts General Hospital investigator discusses how LVADs and mechanical circulatory supports have altered the national heart donor strategy.

The study was specific to Olmsted County, Minnesota, and was the first American population-based study examining the association between hidradenitis suppurativa and these various conditions

The rate of long-term survival after 10 years in patients surviving the initial hospital stay after OHCA was between 62% and 64%.

Theresa R. Cerulli, MD, discusses the known clinical profile and evidential potential of the newest non-stimulant ADHD drug for adults.

Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.

Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.

Jennifer Green discussed weight management and obesity during the annual Pri-Med West conference.

Type 2 diabetes can be more aggressive in younger patients.

There is concern for cardiovascular patients over missed screenings during the pandemic.

Though minocycline therapy has been effective in treating acne, it can often leave erythema and hyperpigmentation which can be mitigated via Intense Pulsed Light.

On the heels of the FDA approval of viloxazine extended-release capsules for adult ADHD, a neuropsychiatrist discusses the state of care and diagnosis among older patients.

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini provide insight from ATTD 2022, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems.

The pandemic has removed some of the barriers of medicine.

Phone communication may have decreased in recent years among doctors.

In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.

Many people struggled with anxiety during the COVID-19 pandemic.

Data show 7 risk factors, many potentially modifiable, accounted for 85% of the risk of first AMI in young women and men.

Exact triggers in acute urticaria and chronic urticaria are largely unknown, with the success of identifying causes of AU varying between 21-68%.

Previous research has suggested that psoriasis could affect both fecundity and fertility, leading to spontaneous abortion and ectopic pregnancy.

From curative stem cell approaches to in-clinic subretinal injections, Arshad Khanani, MD, MA, navigates what the future drug class may entail.

There remains a need for more doctors that specialize in geriatrics.

An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.

Many patients, particularly older ones, are taking unnecessary medications.

The current registered dosing of the therapy is 30 mg twice daily, but the analyzed dosage of 20 mg has not yet been approved.

Early-stage prevention of modifiable risk factors may contribute to the prevention of neurodegenerative changes and diabetic retinopathy.

Similarly, patients affected by alopecia areata had higher odds of developing psoriasis.